Selective inhibition of hepatitis c virus infection by hydroxyzine and benztropine

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3451-3460

  Mingorance, Lidia ^a   Friesland, Martina ^a   Coto Llerena, Mairene ^b   Pérez del Pulgar, Sofía ^b   Boix, Loreto ^b   López Oliva, Juan Manuel ^b   Bruix, Jordi ^b   Forns, Xavier ^b   Gastaminza, Pablo ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZATROPINE; CHLORPROMAZINE; CLOMIFENE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; HYDROXYZINE; IMIPRAMINE; PERPHENAZINE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; VIRUS RNA; ALPHA INTERFERON; MOLECULAR LIBRARY; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; VIRUS ENTRY; WESTERN BLOTTING; BIOASSAY; CELL CULTURE TECHNIQUE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; LIVER; MOLECULAR LIBRARY; POPULATION GENETICS; VIROLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BENZTROPINE; BIOLOGICAL ASSAY; CELL CULTURE TECHNIQUES; DRUG THERAPY, COMBINATION; GENETICS, POPULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; HYDROXYZINE; INTERFERON-ALPHA; LIVER; RIBAVIRIN; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84901271621     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02619-14     Document Type: Article

References (50)

1. Maasoumy B, Wedemeyer H. 2012. Natural history of acute and chronic hepatitis C. Best Pract. Res. Clin. Gastroenterol. 26:401-412. http://dx.doi.org/10.1016/j.bpg.2012.09.009.
2. Guidotti LG, Chisari FV. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1:23-61. http://dx.doi.org/10.1146/annurev.pathol. 1.110304.100230.
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 20 December 2013. Expanded classification of hepatitis C virus into 7 genotypes and 67 Subtypes: updated criteria and assignment Web resource. Hepatology. http://dx.doi.org/10.1002/hep.26744.
4. Ripoli M, Pazienza V. 2011. Impact of HCV genetic differences on pathobiology of disease. Expert Rev. Anti Infect. Ther. 9:747-759. http://dx.doi.org/10.1586/eri.11.94.
5. Pawlotsky JM. 2013. Hepatitis C virus: standard-of-care treatment. Adv. Pharmacol. 67:169-215. http://dx.doi.org/10.1016/B978-0-12-405880-4.00005-6.
6. Ploss A, Evans MJ. 2012. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2:14-19. http://dx.doi.org/10.1016/j.coviro.2011.12.007.
7. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. 2006. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80:1734-1741. http://dx.doi.org/10.1128/JVI. 80.4.1734-1741.2006.
8. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http://dx.doi.org/10.1038/nm.3248.
9. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
10. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants. 2013. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J. Viral Hepat. 20:745-760. http://dx.doi.org/10.1111/jvh. 12173.
11. Lange CM, Jacobson IM, Rice CM, Zeuzem S. 16 September 2013. Emerging therapies for the treatment of hepatitis C. EMBO Mol. Med. http://dx.doi.org/10. 1002/emmm.201303131.
12. Gastaminza P, Whitten-Bauer C, Chisari FV. 2010. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. U. S. A. 107:291-296. http://dx.doi.org/10.1073/pnas.0912966107.
13. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42:3858-3863.
14. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922. http://dx.doi.org/10.1038/nature06205.
15. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74. http://dx.doi.org/10.1099/0022-1317-36-1-59.
16. Armengol C, Tarafa G, Boix L, Sole M, Queralt R, Costa D, Bachs O, Bruix J, Capella G. 2004. Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin. Cancer Res. 10:2150-2157. http://dx.doi.org/10.1158/1078-0432.CCR-03-1028.
17. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299. http://dx.doi.org/10. 1073/pnas.0503596102.
18. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, McKeating JA, Chisari FV. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80:11082-11093. http://dx.doi.org/10. 1128/JVI.01307-06.
19. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. 2008. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol. 82:7034-7046. http://dx.doi.org/10.1128/JVI. 00118-08.
20. Gastaminza P, Pitram SM, Dreux M, Krasnova LB, Whitten-Bauer C, Dong J, Chung J, Fokin VV, Sharpless KB, Chisari FV. 23 March 2011. Antiviral stilbene 1,2-diamines prevent initiation Of hepatitis C viral RNA replication at the outset of infection. J. Virol. http://dx.doi.org/10.1128/JVI.02116-10.
21. Bernhardt G, Reile H, Birnbock H, Spruss T, Schonenberger H. 1992. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J. Cancer Res. Clin. Oncol. 118:35-43. http://dx.doi.org/10.1007/BF01192309.
22. Hoh A, Maier K, Dreher RM. 1987. Multilayered keratinocyte culture used for in vitro toxicology. Mol. Toxicol. 1:537-546.
23. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159. http://dx.doi.org/10.1016/0003-2697(87)90021-2.
24. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitisCvirus assembly, maturation, degradation,and secretion. J. Virol. 82:2120-2129. http://dx.doi.org/10.1128/JVI.02053-07.
25. Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. 2008. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 105:3088-3093. http://dx.doi.org/10.1073/pnas.0712380105.
26. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642. http://dx.doi.org/10.1084/jem.20021756.
27. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-Adaptive mutations. J. Virol. 75:4614-4624. http://dx.doi.org/10.1128/JVI.75.10.4614-4624.2001.
28. Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. 2013. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J. Virol. 87:6377-6390. http://dx.doi.org/10.1128/ JVI.03557-12.
29. Murakami Y, Fukasawa M, Kaneko Y, Suzuki T, Wakita T, Fukazawa H. 2013. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microbes Infect. 15:45-55. http://dx.doi.org/10.1016/j.micinf.2012.10.003.
30. Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D, Cremer PS, Chen Z. 2013. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob. Agents Chemother. 57:2571-2581. http://dx.doi.org/10.1128/AAC.02593-12.
31. Levitz SM, Diamond RD. 1985. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J. Infect. Dis. 152:938-945. http://dx.doi.org/10.1093/infdis/152.5.938.
32. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB. 2003. Inhibition of hepatitis C virus RNA replication by 2-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984. http://dx.doi.org/10.1074/jbc.M210914200.
33. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80:5308-5320. http://dx.doi.org/10.1128/JVI.02460-05.
34. Hu Z, Lan KH, He S, Swaroop M, Hu X, Southall N, Zheng W, Liang TJ. 25 November 2013. Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.02094-13.
35. Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. 2007. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viralRNApolymerase NS5B. J. Biol. Chem. 282:32765-32772. http://dx.doi.org/10.1074/jbc.M704418200.
36. Takeda M, Ikeda M, Mori K, Yano M, Ariumi Y, Dansako H, Wakita T, Kato N. 2012. Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio 2:279-283. http://dx.doi.org/10.1016/j.fob.2012.08.003.
37. Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, Ikezaki H, Hiramine S, Mukae H, Toyoda K, Taniai H, Okada K, Kainuma M, Kajiwara E, Hayashi J. 2012. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 57:1186-1192. http://dx.doi.org/10.1016/j.jhep.2012.08.003.
38. Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D, Maddon PJ, Olson WC. 2012. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One 7:e35351. http://dx.doi.org/10.1371/journal. pone.0035351.
39. Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ. 2010. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6:e1001086. http://dx.doi.org/10.1371/ journal.ppat.1001086.
40. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus- 15 years on. J. Gen. Virol. 85:3173-3188. http://dx.doi.org/10.1099/vir.0.80401- 0.
41. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. 8 November 2013. Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology http://dx.doi.org/10.1002/hep.26567.
42. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. http://dx.doi.org/10.1038/nature05654.
43. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. 2011. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85:596-605. http://dx.doi.org/10.1128/JVI.01592-10.
44. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ. 2013. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. U. S. A. 110:13109-13113. http://dx.doi.org/10.1073/pnas.1221899110.
45. Bush CO, Greenstein AE, Delaney WE, IV, Beran RK. 2013. Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. PLoS One 8:e65273. http://dx.doi.org/10. 1371/journal.pone.0065273.
46. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, Gordon JMFFD, O'Leary JG, Kuo A, Schiano TD, Everson GT, Schiff ER, Befeler A, McHutchison JG, Symonds WT, Denning JM, McNair L, Arterburn S, Moonka D, Gane EJ, Afdhal NH. 2013. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 58:314A. http://dx.doi.org/10.1002/hep. 26727.
47. Ramirez S, Perez-Del-Pulgar S, Carrion JA, Costa J, Gonzalez P, Massaguer A, Fondevila C, Garcia-Valdecasas JC, Navasa M, Forns X. 2009. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am. J. Transplant. 9:1591-1601. http://dx.doi.org/10.1111/j.1600-6143.2009. 02666.x.
48. Simons FE, Simons KJ, Frith EM. 1984. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J. Allergy Clin. Immunol. 73:69-75. http://dx.doi.org/10.1016/0091-6749(84) 90486-X.
49. Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ. 1989. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J. Clin. Pharmacol. 29:809-815. http://dx.doi.org/10.1002/j. 1552-4604.1989.tb03424.x.
50. Carranza M, Snyder MR, Shaw JD, Zesiewicz TA. 2013. Parkinson's disease. SEEd Medical Publishers, Turin, Italy.